CNBC's David Faber reports Allergan will hold a special meeting on December 18th as Valeant Pharmaceuticals and investor Bill Ackman seek to remove a majority of Allergan's board.» Read More
Securities regulators are looking into the joint bid by Valeant Pharmaceuticals and activist investor Bill Ackman for Allergan, Dow Jones reported.
Bill Ackman is planning to raise around $4 billion by listing a new investment vehicle in London, the FT reports.
CNBC's David Faber discusses just how hard hostiles are for companies to execute, after the canceled unsolicited bid between Time Warner and 21st Century Fox, and other companies recently. Faber provides an update on Valeant's battle for Allergan.
*Equities have come under pressure because of the problems between Russia and Ukraine, with the S&P 500 at one point down about 4 percent from a record closing high in late July. *The gain implied by futures came despite ongoing concerns about the region, with Ukraine reporting that Russia had massed 45,000 troops on its border.
When Rupert Murdoch and Masayoshi Son walked away from their deals last week, the moguls created a shock wave on Wall Street.
Aug 8- The federal judge in California overseeing Allergan Inc's insider trading lawsuit against Valeant Pharmaceuticals and activist investor William Ackman has set an Aug. 20 hearing date to decide on a fast-track schedule for the case, according to court documents.
Some of Friday's midday movers:
The "Fast Money" traders share their final trades of the day.
Aug 6- Institutional Shareholder Services is backing activist investor Bill Ackman's call for a special meeting of Allergan Inc investors that could topple the company's board and increase the chances of a takeover by Valeant Pharmaceuticals International.
Aug 6- Institutional Shareholder Services is backing activist investor Bill Ackman's call for a special meeting of Allergan Inc investors that could topple the Botox-maker's board and increase the chances of a takeover by Valeant Pharmaceuticals International.
Some of Tuesday's midday movers:
A lawsuit by Allergan says the unusual arrangement by Valeant Pharmaceuticals and activist investor Bill Ackman amounts to insider trading.
Ackman's Pershing Square Holdings fund has risen 27.2 percent after extending its gains modestly while many hedge fund managers suffered losses.
BOSTON, Aug 4- Billionaire investor William Ackman's Pershing Square Holdings has risen 27.2 percent this year, according to an investor in the fund, after extending its gains modestly last month when many hedge fund managers suffered losses.
Aug 1- Botox maker Allergan Inc on Friday accused rival Valeant Pharmaceuticals International and billionaire investor William Ackman of violating securities laws by using insider information as they prepared a takeover bid for the drug company.
Allergan is suing Valeant, Bill Ackman and his firm Pershing Square for allegedly violating insider trading laws. Marc LoPresti of LoPresti Law Group, and CNBC's Robert Frank dissect the lawsuit.
Some of Friday's midday movers:
Allergan sued Valeant Pharmaceuticals and Pershing Square Capital, alleging both acted inappropriately in their hostile $53 billion bid.
CNBC's David Faber reports Allergan has filed a lawsuit against Valeant Pharmaceuticals and Pershing Square's Bill Ackman alleging a violation of federal securities laws.
Some of Thursday's midday movers: